Baxalta $SHPG and CTI BioPharma $CTIC have inked an agreement under which Baxalta will be returning pacritinib to CTIC. As per the terms of the deal, Baxalta will pay CTI a one-time cash payment of $10.3 million as reimbursement for certain incurred or anticipated expenses. CTI will repay the $10.3 million upon the first regulatory approval or any pricing/ reimbursement approval of any product containing pacritinib. The original partnership agreement was with Baxter International, started in 2013. Baxalta, now Shire, faced difficulty in developing the drug following mixed-results in a mid-stage myelofibrosis clinical trial and an FDA clinical hold due to certain side effect.